Upcoming event

Top 5 winter reads on kidney cancer

As many of Game of Thrones fan might say “Winter is coming” and for most of you it is already here. Christmas break is a wonderful time to spend with family and friends. It is also an opportunity to eventually read the novel you have been procrastinating for weeks!

For this winter break, UROONCO has better plans for you. We have selected top 5 kidney cancer game changer and / high quality papers published in 2018.

1. Carmena trial published in the NEJM. In this trial, patients were randomized to receive either sunitinib alone or cytoreductive nephrectomy followed by sunitinib.  Ultimately, median overall survival (OS) with sunitinib alone was noted to be non-inferior to the cytoreductive nephrectomy followed by sunitinib group. We also recommend the accompanying editorial by Robert Motzer and Paul Russo in the same issue.

2. Surtime trial examined whether a period of sunitinib therapy before cytoreductive nephrectomy improves outcome compared with immediate followed cytoreductive nephrectomy by sunitinib. Flaws due to poor accrual taken apart, more patients received sunitinib and OS results were higher in the deferred group. The trial suggested pretreatment with sunitinib may identify patients with inherent resistance to systemic therapy before planned surgery.

3. Checkmate 214 trial is the first trial to introduce the combination of immunotherapy agents in the first line treatment of metastatic renal cell carcinoma. The trial demonstrated overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma.

4. The TRACERx Renal Consortium published a comprehensive study comprehensive picture of the genetic underpinnings and the evolutionary patterns of metastasis. Specifical the hallmark genomic drivers of ccRCC metastasis are loss of 9p and 14q.

5. Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. Young et al. generated more than 72,000 single-cell transcriptomes from healthy and cancerous human kidneys. From these data, they determined that Wilms tumor, a pediatric kidney cancer, originates from aberrant fetal cells, whereas adult kidney cancers are likely derived from a specific subtype of proximal convoluted tubular
cell.

We hope you enjoyed the readings and looking forward for your comments. Best wishes for everybody.